Source
Division of Infectious Diseases, Stony Brook University School of Medicine, Health Sciences Center T15-080, Stony Brook, NY 11794-8153, USA. lisa.chirch@stonybrook.edu
Abstract
BACKGROUND:
Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is now available for the treatment of drug-resistant virus.
OBJECTIVE:
To establish raltegravir as an effective addition to the existing antiretroviral armamentarium by reviewing pharmacokinetics, efficacy, safety and tolerability.
METHODS:
Data from pharmacokinetic, Phase II and III clinical trials were reviewed.
RESULTS/CONCLUSIONS:
Results from clinical trials indicate that raltegravir is safe and highly effective in the treatment of both antiretroviral-naïve and -experienced patients.